Altre lingue MediWound Ltd.

Azioni

MDWD

IL0011316309

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 17/04/2024			Variaz. 5gg	Var. 1 gen.
17,44 ^USD	-4,60%		+14,14%	+71,48%

21/03	MediWound Ltd. Fornisce una guida alle entrate per gli anni 2025 e 2026	CI
21/03	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	21/03
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M	21/03
MediWound: Q4 Earnings Snapshot	21/03
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	21/03
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	14/03
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	14/03
Sector Update: Health Care Stocks Mixed Late Afternoon	12/02
MediWound Shares Rise After Positive Results From EscharEx Comparison Study	12/02
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study	12/02
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study	12/02
MediWound to Participate in Two Upcoming Investor Conferences	05/02
MediWound to Participate in Two Upcoming Investor Conferences	05/02
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA	09/01
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army	29/12
MediWound Secures $6.7 Million in DoD Funding for Field Burn Treatment Therapy	28/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue MediWound Ltd.

Azioni

MDWD

IL0011316309

Altre lingue

Filtri